This article has been corrected. Please see J Manag Care Spec Pharm. 2020;26(8):1039-49.
Effectiveness and Costs Among Rheumatoid Arthritis Patients Treated with Targeted Immunomodulators Using Real-World U.S. Data.
Gharaibeh M, Bonafede M, McMorrow D, Hernandez EJM, Stolshek BS. J Manag Care Spec Pharm. 2020;26(8):1039-49.
The authors would like to make the following corrections to the above article:
Page 1042, the second paragraph, under Nonadherence, should be corrected as shown (change shown in bold):
“For self-administered drugs (abatacept administered subcutaneously [SC], adalimumab, certolizumab pegol, etanercept, golimumab SC, and tocilizumab SC) and tofacitinib, nonadherence was defined as medication possession ratio (MPR) of ≤ 80%. MPR was calculated as the total days supply for the index therapy divided by the total follow-up days (365 days fixed follow-up period). If a patient refilled a medication before the previous days supply running out, the days supply was extended for a maximum of 14 days (allowing for 14 days of overlap). For infused drugs (abatacept, golimumab, and tocilizumab), a proportion of days covered (PDC) of ≤ 80% was calculated using the expected duration of clinical benefit.”
While the authors regret these errors, they do not affect the conclusions of the article.